Biotechnology Gilead’s Aggressive Push Beyond HIV Treatments – Plans To Increase Cancer-Focused CAR-T Treatment Production – Gilead Sciences (NASDAQ:GILD) Read more
Biotechnology CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst – CymaBay Therapeutics (NASDAQ:CBAY), Gilead Sciences (NASDAQ:GILD) Read more
Eurozone Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B – Big Lots (NYSE:BIG), AN2 Therapeutics (NASDAQ:ANTX) Read more
Biotechnology Why Is CymaBay Therapeutics Stock Trading Higher Today? – CymaBay Therapeutics (NASDAQ:CBAY), Gilead Sciences (NASDAQ:GILD) Read more
